News

SORT BY YEAR
9 May, 2020

Ally Bridge Portfolio News – GRAIL Announces $390 Million Series D Financing

MENLO PARK, Calif. — (BUSINESS WIRE) — GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced a $390 million Series D financing round. New investors including Public Sector Pension Investment Board (PSP Investments) and Canada Pension Plan Investment Board (CPP Investments), as well as two […]

Read More
6 May, 2020

Ally Bridge Group Leads Pulmonx’s $66mn Financing to Support Commercial Acceleration of the Zephyr Valve System

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally-invasive treatment for patients with severe emphysema, announces a $66 million financing led by Ally Bridge Group, a leading global life science investor. The financing also attracted new investors Adage Capital Management, HealthQuest Capital, Partner Fund Management, and Rock Springs Capital, as […]

Read More
1 May, 2020

Ally Bridge Group Leads Vida Health’s $25mn Financing to Scale Network and Meet Increased Demand for Virtual Care

San Francisco, April 30, 2020 — Virtual healthcare platform, Vida Health, announced today that it raised $25 million in new funding to meet the increased demand for mental and physical virtual care. The funding was led by Ally Bridge Group (ABG), a leading global life science investment firm. Returning investors include Yahoo! founder Jerry Yang’s […]

Read More
16 March, 2020

Ally Bridge Portfolio News – WuXi Biologics and Vir Biotechnology Announce Collaboration for Global Development of Antibodies to Treat COVID-19

SAN FRANCISCO and SHANGHAI, Feb. 25, 2020 /PRNewswire/ — WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Vir Biotechnology, Inc. (“Vir”) (Nasdaq: VIR) today announced a development and manufacturing collaboration to advance and produce human monoclonal antibodies for the potential treatment of Coronavirus Disease 2019 (COVID-19), a […]

Read More
21 February, 2020

Ally Bridge Group leads $30 mln investment in Israel’s Mavrik Dental

JERUSALEM, Feb 18 (Reuters) – Israel’s Mavrik Dental Systems has raised $30 million in a funding round led by life sciences investment firm Ally Bridge Group (ABG), the companies said on Tuesday. Mavrik provides technologies for in-office dental treatment. Following ABG’s investment, Mavrik will move commercial operations to the United States while keeping its product […]

Read More
19 February, 2020

Ally Bridge Group Leads US$70 million Investments in Two Israeli Life Science Companies over the Last 2 Months

TEL AVIV, Israel, HONG KONG and NEW YORK, Feb. 18, 2020 /PRNewswire/ — Ally Bridge Group (“ABG”), a leading global life science investment group, has announced that it recently led US$70 million investments in two Israeli life sciencecompanies over the last 2 months. Each of the two companies is a commercial-stage, leading innovator re-setting the standard of care in its respective area. They include: […]

Read More
16 December, 2019

Ally Bridge Group Leads More Than US$140 million in Financings for Three New Medtech Investments, Bringing Total Ally Bridge-led Private Life Science Investments to Above US$500 million over the Last 18 Months

HONG KONG and NEW YORK, Dec. 16, 2019 /PRNewswire/ — Ally Bridge Group (“ABG”), a leading global life science investment group, has announced that it recently led investments in three new medical technology companies. Each of the three companies is a commercial-stage, leading innovator re-setting the standard of care in its respective category. They include: Imperative Care (Campbell, CA) — A […]

Read More
11 December, 2019

Ally Bridge Group Co-leads Imperative Care’s $85 Million Series C Financing

CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc. today announced that it has completed the initial closing of a Series C financing of $85 million to support the commercial launch of the company’s portfolio, which is composed of the latest advances in neurovascular devices treating ischemic and hemorrhagic strokes. The round was co-led by new investors Ally Bridge […]

Read More
4 December, 2019

Ally Bridge Group Leads Venclose’s $27 Million Series C Funding

SAN JOSE, Calif., Dec. 3, 2019 /PRNewswire/ — Venclose, Inc., a privately-held Silicon Valley medical device company focused on innovative treatment procedures for venous reflux disease, today announced it has closed its Series C funding led by Ally Bridge Group (ABG). ABG is a global life science-focused group with a successful investment record globally in supporting high-growth innovative life […]

Read More
10 May, 2019

Ally Bridge Portfolio News – Pulmonx Closes $65 Million Financing and Adds Chief Financial Officer

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Pulmonx Corporation, a global leader in diagnostic and therapeutic pulmonary device technologies, announced today the closing of an oversubscribed $65 million equity financing and the hiring of Derrick Sung, Ph.D. as its Chief Financial Officer. The financing was led by Ally Bridge Group, a leading global life science-dedicated investment group, and included other […]

Read More